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OBJECTIVE: The objective of this selective EBM review is to determine whether or not there 
is a mortality benefit with the use of aspirin in the primary prevention setting in adults without 
cardiovascular disease.  
 
STUDY DESIGN: This is a systematic review of three double blind randomized controlled 
trials published in 2018. All three trials compared 100 mg of aspirin with placebo and were 
published in English. 
 
DATA SOURCES: All three articles were identified and published through peer-reviewed 
sources using PubMed.  
 
OUTCOMES MEASURED: Mortality was the outcome measured through various death 
identification steps such as review of death certificates, notification from next of kin, and review 
of medical records. 
 
RESULTS: The ASPREE trial showed that aspirin was associated with an increase in all-cause 
mortality. There was 5.9% mortality in the aspirin group versus 5.2% in the placebo group with 
statistically significant results (p-value < 0.05) (McNeil JJ, Nelson MR, Woods RL, et al. N Engl 
J Med. 2018;379(16):1519-1528. doi: 10.1056/NEJMoa1803955 [doi]). The ARRIVE trial 
showed that participants taking aspirin had a 1% reduced risk of mortality compared to those 
taking the placebo (hazard ratio = 0.99) (Gaziano JM, Brotons C, Coppolecchia R, et al. Lancet. 
2018;392(10152):1036-1046. doi: S0140-6736(18)31924-X [pii]). However, the results were not 
statistically significant with a p-value > 0.05. The ASCEND trial showed that those taking 
aspirin have a reduced risk of death compared to those taking the placebo (rate ratio = 0.94) 
(Bowman L, Mafham M, Wallendszus K, et al. N Engl J Med. 2018;379(16):1529-1539. doi: 
10.1056/NEJMoa1804988 [doi]). These results were not statistically significant (p-value > 0.05). 
 
CONCLUSIONS: The data did not show that the use of aspirin in the primary prevention 
setting has a mortality benefit in adults without cardiovascular disease. ASPREE was the only 
trial that had statistically significant results and it showed a higher rate of mortality in those 
taking aspirin. ASCEND and ARRIVE trials showed a small mortality benefit in those taking 
aspirin. However, these findings were not statistically significant. These compelling findings 
need to be investigated further with large scale studies using mortality as a primary investigative 
endpoint. 
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INTRODUCTION 
 Cardiovascular disease (CVD) is a term that encompasses a collection of disorders that 
involve the heart and blood vessels such as coronary artery disease, peripheral vascular disease, 
and cerebrovascular disease. Globally, CVD is the leading cause of death among adults from 
clinical events such as acute myocardial infarction and cerebrovascular accident.1 Primary 
prevention is a term used to describe actions and efforts aimed at avoiding a specific disease. In 
other words, primary prevention is aimed at preventing a disease from manifesting in an 
otherwise healthy individual. Secondary prevention is a term used to describe actions and efforts 
aimed at lessening the severity or slowing the progression of a disease that has already 
manifested. The usual methods of primary and secondary prevention of CVD include diet, 
exercise, avoidance of tobacco, and controlling comorbidities such as dyslipidemia, diabetes 
mellitus (DM), and hypertension. What makes these preventative measures primary or secondary 
is whether or not an individual has developed the disease. 
 Aspirin use as a primary prevention measure is extremely common, despite the absence 
of strong evidence. Millions of individuals report taking aspirin as a primary prevention strategy, 
without a known history CVD, according to data from the 2017 National Health Interview 
Survey (NHIS).2 The majority of these individuals were doing so without instruction from their 
physician.2 Public fear of CVD is warranted with staggering statistics on costs, hospitalizations, 
and long term disabilities. The healthcare costs involved with long-term care and the acute phase 
of CVD are substantial. It is estimated that $329.7 billion is spent each year in the US on CVD.3 
It is projected that CVD will cost $749 billion in the year 2035.3 In 2016, 2.2 million people 
were hospitalized for stroke, myocardial infarction, and heart failure.4 
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 A meta-analysis of RCTs by the Antithrombotic Trialists’ Collaboration has shown an 
irrefutable benefit of long-term aspirin use as secondary prevention in patients with known 
CVD.5 That strategy is fundamental in the established guidelines in the American College of 
Cardiology regarding treatment of patients with established disease. The use of aspirin, having 
antithrombotic effects by inhibiting platelet function, involves an increased risk of bleeding. It is 
unclear whether or not the use of aspirin in the primary prevention setting in adults without 
cardiovascular disease is beneficial enough to outweigh the known bleeding risk. This paper 
evaluates three RCTs comparing the effects of aspirin in the primary prevention setting in adults 
without CVD. Specifically, this systematic review has a primary focus of examining effects on 
mortality. 
OBJECTIVE  
 The objective of this selective evidence-based medicine review is to determine whether 
or not there is a mortality benefit with the use of aspirin in the primary prevention setting in 
adults without cardiovascular disease. 
METHODS  
 This systematic review utilized three randomized, double-blind, placebo-controlled trials. 
All articles were published in peer-reviewed journals. They were selected based on relevance to 
the clinical question and chosen on the basis that the outcomes of the studies mattered to 
patients, POEMs (Patient-Oriented Evidence that Matters). PubMed was used to identify 
appropriate articles using the key words, “aspirin,” “primary prevention,” and “cardiovascular 
disease.” Studies were considered if they were published within the last 10 years from the date of 
the search strategy (2008-2018). However, all three articles selected were published in 2018. 
Exclusion criteria included children, adolescents, adults younger than 40, and data published 
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before 2008. See table 1 for the inclusion and exclusion criteria utilized by the investigators of 
each study that was included in this systematic review.   
In order to best answer the clinical question, specific criteria were used to narrow down 
selection of studies. The population considered was adults without cardiovascular disease older 
than 40 years old. Each RCT had slightly unique population criteria. The ASPREE population 
was adults ≥ 70 or ≥ 65 among blacks and Hispanics. The ASCEND trial included individuals ≥ 
40 years old with DM but no evidence of CVD. The ARRIVE trial focused on men 55 and older 
and women 60 years and older who had an average cardiovascular risk (between two and four 
risks factors for men and three or more for women). The risks factors included current smoking 
(any in the last 12 months), low HDL cholesterol (< 40 mg/dL), high blood pressure (systolic > 
140 mmHg), receiving medication to treat high blood pressure, positive family history of 
cardiovascular heart disease, high cholesterol (total cholesterol > 200 mg/dL or LDL > 130 
mg/dL for men; total cholesterol > 240 mg/dL or LDL > 160 mg/dL for women). The 
intervention was 100 mg of enteric-coated aspirin. The treatment group receiving aspirin was 
compared to the group who received placebo. This systematic review focuses specifically on the 
outcome of mortality. 
The statistic methodology analyzed by each study differed slightly. The number needed 
to harm (NNH) was calculated for each RCT and all three included 95% confidence intervals 
(CI). ARRIVE and ASPREE reported p-values and hazard ratios. ASCEND used a rate ratio.  
OUTCOMES MEASURED  
The outcome measured for this systematic review was mortality. Mortality was measured 
by various methods of death identification. In the ASPREE trial, death was identified when 
failure to attain contact with participants occurred.6 Investigators reviewed health records, death 
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Table 1. Demographics & Characteristics of Included Studies  
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notices, and obituaries.6 Sometimes family members would notify the trial investigators. Two 
independent sources were required for death identification such as from family members, 
primary care physicians, or public death notices.6 In the ARRIVE trial, participants would 
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undergo follow-up from primary care physicians during face-to-face meetings, over the phone, 
and through medical record reviews.8 The ASCEND trial death identification involved methods 
similar to both ARRIVE and ASPREE with the use of adjudication and review of death 
certificates and information about events prior to the death.7 
RESULTS 
  This selective EBM used three RCTs to determine whether there is a mortality benefit 
with the use of aspirin in adults without cardiovascular disease. All three studies were double-
blind, randomized controlled trials. To avoid bias, neither the participants nor the researchers 
knew who was receiving aspirin or placebo. Each study used a slightly unique population, as 
seen in table 1. However, all participants were adults over 40 years old without a history of 
cardiovascular disease.  
 The ASPREE trial, which stands for the “Aspirin in Reducing Events in the Elderly,” 
focused on people who were 70 years old or older (or ≥ 65 years of age for blacks and 
Hispanics).6 The trial included people from the United States and Australia. Recruitment in 
Australia was primarily through the participant’s primary care physician.6 Recruitment in the 
United States was primarily done through the community via academic health centers.6 The total 
number of participants in the ASPREE trial was 19,114; the group who received aspirin had 
9,525 people and the group who received placebo had 9,589 people.6 In the aspirin group, 139 
participants were lost to follow-up and 118 withdrew consent.6 In the placebo group, 157 
participants were lost to follow-up and 119 withdrew their consent.6 Over a median of 4.7 years, 
a total of 1,052 deaths occurred.6 There was 5.9% all-cause mortality in the aspirin group and 
5.2% in the placebo group (p-value = 0.03).6 Statistical analysis showed a hazard ratio of 1.14 
(95% CI: 1.01-1.29).6 This can be interpreted as the aspirin group had a 14% increased risk of 
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mortality as compared to placebo. The number needed to harm (NNH) was 141. These results 
were statistically significant.  
Table 2. All-cause mortality statistics in the ASPREE trial 
Study NNH Hazard Ratio Confidence 
Interval (CI) 
P-value 
ASPREE 141 1.14 1.01-1.29 0.03 
 
The ARRIVE trial, which stands for “Aspirin to Reduce Risk of Initial Vascular Events,” 
had a patient population of patients aged 55 years (men) or 60 years (women) and older who had 
an average cardiovascular risk.8 Further details of cardiovascular risk details, inclusion, and 
exclusion criteria can be found in the methods section of this paper. The study involved patients 
from Germany, Italy, Poland, Ireland, Spain, the UK, and the USA in the setting of a primary 
care office. The total number of participants was 12,546.8 They were randomly assigned to 
receive aspirin (6,270 participants) or placebo (6,276).8 Over the course of approximately 6 
years, participants had 9 visits with their primary care provider and key variables were recorded.8 
In the aspirin group, 1,843 participants withdrew from the study.8 In the placebo group, 1,875 
withdrew.8 There were 277 deaths during the length of the trial.8 Statistical analysis showed a 
hazard ratio of 0.99 with a 95% confidence interval of 0.80-1.24.8 The p-value was 0.9459.8 This 
can be interpreted as those taking aspirin have a 1% reduced risk of mortality compared to those 
taking placebo. However, these results were not statistically significant. 
Table 3. All-cause mortality statistics from the ARRIVE trial 
Study NNH Hazard ratio Confidence 
Interval (CI) 
P-value 
ARRIVE  5,000 0.99 0.80-1.24 0.9459 
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The ASCEND trial, which stands for “A Study of Collaborative Events iN Diabetes,” 
focused on adults over 40 years old with diabetes, but no manifestations of cardiovascular 
disease.7 Recruitment was done using regional diabetes registers or primary care offices in the 
United Kingdom.7 All types of diabetes were included.7 Confirmed participants were sent a 6 
month supply of 100 mg of aspirin or a matching placebo pill, as well as 1 gram capsules of 
omega-3 fatty acid or a matching placebo capsule.7 Therefore, ASCEND had a 2x2 factorial 
blinded design.7 All pills and capsules were to be taken once daily.7 These supplies and a 
questionnaire were sent every 6 months during the trial.7 For the purpose of this systematic 
review, data were focused on aspirin versus placebo. The questionnaires recorded information 
such as serious adverse events, trial regimen adherence, use of other antiplatelet or 
anticoagulation, events causing discontinuation of the trial procedure, and any symptomatic 
bleeding episodes that caused the patients to seek medical attention.7 A total of 15,480 
participants were randomized; 7,740 patients in each group.7 Participants were followed for a 
mean follow-up period of 7.4 years.7 There was a total of 1,540 deaths during the trial.7 A total 
of 69 participants in the aspirin group and 70 participants in the placebo group yielded 
incomplete follow-up information at the culmination of the trial.7 Reasons for incomplete follow-
up information include withdrawal of consent, participants moving abroad, and death.7 748 
deaths occurred in the aspirin group and 792 deaths in the placebo group.7 The statistical analysis 
showed that participants taking the aspirin had 0.94 times risk of mortality, using a rate ratio.7 In 
other words, they had a slightly decreased risk of mortality compared to the participants taking 
placebo. The confidence interval was 0.85-1.04.7 Therefore, the result of aspirin decreasing risk 
of mortality was not statistically significant (p-value > 0.05). 
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Table 4. All-cause mortality statistics from the ASCEND trial 
Study NNH Rate ratio Confidence 
Interval (CI) 
P-value 
ASCEND 175 0.94 0.85-1.04 > 0.05 
 
DISCUSSION 
 Cardiovascular disease is one of the major causes of morbidity and mortality worldwide. 
In the US, one out of every three deaths is from CVD and it causes more deaths than cancer and 
chronic pulmonary diseases combined.3 Given the solid evidence for the use of aspirin in 
individuals who have already had a cardiovascular event, it is plausible to propose that there may 
be benefit for people in the primary prevention setting in an attempt to avoid cardiovascular 
events and prevent premature mortality. Unfortunately, aspirin is not void of risks. Aspirin is an 
antiplatelet medication, thinning the blood and making it easier to have bleeding complications. 
Additionally, there is risk of an allergic reaction or drug interactions.  
 The three randomized control trials showed no statistically significant mortality benefit in 
the use of aspirin in the primary prevention strategy. Moreover, ASPREE had statistically 
significant results that those taking aspirin had a higher all-cause mortality than the participants 
assigned to take placebo. This higher all-cause mortality was attributed to cancer.6 There was no 
clear tie to a specific type of cancer or tumor location.6 However, the broad category of 
gastrointestinal cancer was a large contributor to cancer-related mortality.6 Of note, ASPREE 
had the oldest participant population. Advancing age is the number one risk factor in the 
development of various individual cancer types.9 Therefore, the relationship between an older 
patient population and the leading cause of cancer-related deaths as the major cause of mortality 
is a possible limitation to this study. Additionally, there was a statistically significant rate of 
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hemorrhage in the aspirin group compared to placebo with a hazard ratio of 1.38 (95% CI: 1.18-
1.62; p-value < 0.001).6 The strengths of this study include the large sample size, randomized 
and blinded study design, and ease of access to clinical records, which allowed the investigators 
to obtain accurate and complete information. Other limitations include the relatively short 
follow-up period and specific age range of participants, limiting the statistical power of the 
results and ability to generalize to the broader U.S. population.  
 The ARRIVE trial did not demonstrate a statistically significant reduction in mortality 
using a primary prevention aspirin strategy. It found a small, insignificant reduction of mortality 
in adults with average risk of CVD (10-year risk of 10-20%) who took aspirin. Of note, there 
was a statistically significant risk of gastrointestinal bleeding in the aspirin group (p-value = 
0.0007).8 ARRIVE had participants from seven countries, including the US, making the data the 
most generalizable out of the three RCTs. Other strengths include the large sample size, 
randomized and blinded study design, and the practicality of the primary care setting. During the 
study, there was public media discussion on the uncertainty of aspirin in the primary prevention 
setting in the UK.8 The results from the UK reflected a difference compared to the other 
countries including a high rate of withdrawal from the study.8 This is a limitation to the ARRIVE 
trial. Other limitations include identifying a population with true moderate risk of CVD and 
compliance.  
 The ASCEND trial also did not show a statically significant reduction in mortality in the 
aspirin group compared to placebo. Like the ARRIVE trial, the rate of major hemorrhagic 
bleeding events was statistically significantly higher in the aspirin group (p-value = 0.003).7 
Strengths of the study include the randomized and blinded study design, large sample size, and 
nearly complete follow-up information. ASCEND had its own limitations. It was a trial 
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completed only in the UK, narrowing the generalizability. The patient population was individuals 
with all types of diabetes, a specific group of patients that often have high rates of comorbidities 
and complications from their disease. Another limitation is that there was speculation that there 
was an association of diabetes and reduced efficacy of aspirin.7 However, the study did not 
appear to support this.7 In addition to aspirin, participants were randomized to take omega-3 fatty 
acid capsules or a placebo, which could be a confounding variable.   
CONCLUSIONS 
 Is there a mortality benefit with the use of aspirin in the primary prevention setting in 
adults without cardiovascular disease? According to the data from this systematic review of three 
randomized, double-blind, placebo-controlled trials, the answer to this clinical question is no. 
The lack of a mortality benefit utilizing aspirin in a primary prevention strategy was consistent 
across these three trials. The only statistically significant results were from the ASPREE trial and 
the data was on the contrary. The use of aspirin was associated with a higher rate of all-cause 
mortality. Inherent potential limitations were identified in all three trials. However, the totality of 
the patient populations yielding the same conclusion is compelling. Consistently, a statistically 
significant increased risk of bleeding in patients on aspirin was identified in all three trials. In 
conclusion, the evidence to support the use of aspirin to lower an individual’s mortality risk is 
not supported by the three aforementioned trials. The specific patient population of adults at high 
risk for developing CVD, but without CVD, was not included in these three RCTs. Therefore, 
the decision to incorporate aspirin into a patient’s daily regimen should be an individual choice, 
unique to each patient’s cardiovascular risk. It should be a collaborative decision between the 
individual and their healthcare provider. Consistent with standard medical practice, the risks and 
benefits must always be weighed. Decisions should be based upon evidence-based, 
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contemporary data. To definitively answer this clinical question, it will likely require ongoing 
large, diverse, and long-term studies perhaps focusing on specific high risk and low risk groups 
of patients.  
  
REFERENCES  
1. World Health Organization. About cardiovascular diseases. World Health Organization 
Web site. https://www.who.int/cardiovascular_diseases/about_cvd/en/. Updated 2019. 
Accessed November 25, 2019. 
 
2. Diaz-MacInnis L. More harm than good: Researchers find widespread aspirin use despite 
few benefits, high risks. Beth Israel Deaconess Medical Center Web 
site. https://www.bidmc.org/about-bidmc/news/2019/07/more-harm-than-good---
researchers-find-widespread-aspirin-use-despite-few-benefits-high-risks. Updated 2019. 
Accessed October 4, 2019. 
 
3. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics 2018. 
American Heart Association Web site. https://healthmetrics.heart.org/wp-
content/uploads/2018/02/At-A-Glance-Heart-Disease-and-Stroke-Statistics-2018.pdf. 
Updated 2018. Accessed October 4, 2019. 
 
4. Ritchey M, Wall H, Owens P, et al. Vital signs: State-level variation in nonfatal and fatal 
cardiovascular events targeted for prevention by million hearts 2022. Centers for Disease 
Control and Prevention Web site. 
https://www.cdc.gov/mmwr/volumes/67/wr/mm6735a3.htm. Updated 2018. Accessed 
October 7, 2019. 
 
5. Hennekens C. Aspirin for the secondary prevention of atherosclerotic cardiovascular 
disease. UpToDate Web site. https://www.uptodate.com/contents/aspirin-for-the-
secondary-prevention-of-atherosclerotic-cardiovascular-disease. Updated 2019. Accessed 
October 4, 2019. 
 
6. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the 
healthy elderly. N Engl J Med. 2018;379(16):1519-1528. doi: 10.1056/NEJMoa1803955 
[doi]. 
 
7. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention 
in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529-1539. doi: 
10.1056/NEJMoa1804988 [doi]. 
 
8. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial 
vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A 
randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-1046. 
doi: S0140-6736(18)31924-X [pii]. 
 
9. National Cancer Institute. Age and cancer risk. National Cancer Institute Web 
site. https://www.cancer.gov/about-cancer/causes-prevention/risk/age. Updated 2015. 
Accessed December 1, 2019. 
 
 
